Armagen - Company & Market Research Reports

ArmaGen is a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Currently, ArmaGen has eight compounds in development. The company’s lead product candidates are AGT-182 for Hunter syndrome, which is in Phase 1 clinical trials, and AGT-181 for Hurler syndrome, which is in Phase 2 trials. ArmaGen’s headquarters and research operations are located in Calabasas, CA.

From
From
From
From
From
From
From
From
From
From
Rett Syndrome - Pipeline Review, H2 2018 - Product Thumbnail Image

Rett Syndrome - Pipeline Review, H2 2018

  • Drug Pipelines
  • 122 Pages
From
From
Rett Syndrome - Pipeline Review, H1 2018 - Product Thumbnail Image

Rett Syndrome - Pipeline Review, H1 2018

  • Drug Pipelines
  • 114 Pages
From
From
From
Parkinson's Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Parkinson's Disease - Pipeline Review, H1 2018

  • Drug Pipelines
  • 881 Pages
From
Loading Indicator
adroll